Aripiprazole

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Psychotic Depression

Conditions

Psychotic Depression

Trial Timeline

Jun 1, 2003 → Jan 1, 2008

NCT ID

NCT00556140

About Aripiprazole

Aripiprazole is a phase 3 stage product being developed by Bristol Myers Squibb for Psychotic Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00556140. Target conditions include Psychotic Depression.

What happened to similar drugs?

2 of 6 similar drugs in Psychotic Depression were approved

Approved (2) Terminated (4) Active (1)

✅Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved

✅Ziprasidone HCL (oral)PfizerApproved

❌quetiapineAstraZenecaPhase 3

🔄QuetiapineAstraZenecaPhase 3

❌QuetiapineAstraZenecaPhase 3

❌mifepristone + placeboCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01386086	Phase 3	Completed	Jun 1, 2011	Nov 1, 2013	Postpartum Depression
NCT00665444	Pre-clinical	Terminated	Apr 1, 2008	Aug 1, 2009	Bipolar Disorder
NCT00308074	Phase 2	Completed	Feb 1, 2006	Feb 1, 2009	Autism
NCT00619190	Phase 2	Completed	Jan 1, 2006	Jun 1, 2012	Autistic Disorder
NCT00608543	Approved	Completed	Oct 1, 2005	Jan 1, 2009	Major Depressive Disorder
NCT00312598	Pre-clinical	Completed	Aug 1, 2005	Apr 1, 2010	Schizophrenia
NCT00221416	Phase 3	Completed	Jun 1, 2005	Dec 1, 2008	Bipolar Disorder
NCT00221962	Approved	Completed	Apr 1, 2005	Apr 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00209027	Pre-clinical	Terminated	Apr 1, 2005	Apr 1, 2011	Schizophrenia
NCT00438386	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Generalized Anxiety Disorder
NCT00374348	Pre-clinical	Completed	Mar 1, 2005	May 1, 2008	Schizophrenia OCD
NCT00208169	Approved	Completed	Mar 1, 2005	Jun 1, 2007	Schizophrenia
NCT00220636	Approved	Completed	Mar 1, 2005	Jan 1, 2008	Depressive Disorder, Major
NCT00198055	Phase 2	Completed	Jan 1, 2005	Sep 1, 2007	Asperger's Disorder
NCT00250705	Approved	Completed	Nov 17, 2004	Mar 23, 2009	Conduct Disorder
NCT00222833	Approved	Completed	Oct 1, 2004	Dec 1, 2005	Overweight
NCT00223496	Approved	Completed	Sep 1, 2004	Sep 1, 2009	Bipolar Disorder
NCT00226317	Pre-clinical	Completed	Apr 1, 2004	Feb 1, 2008	Bipolar Disorder
NCT00194038	Approved	Completed	Apr 1, 2004	Jun 1, 2006	Bipolar Disorder
NCT00224822	Approved	Completed	Mar 1, 2004	Mar 1, 2007	Schizophrenia

Competing Products

14 competing products in Psychotic Depression

See all competitors

Product	Company	Stage	Hype Score
Olanzapine, Amantadine + Olanzapine and placebo	Eli Lilly	Phase 1	29
risperidone IR and LAI formulation	Johnson & Johnson	Phase 1	29
quetiapine	AstraZeneca	Phase 3	32
Quetiapine	AstraZeneca	Phase 3	40
Quetiapine	AstraZeneca	Phase 3	32
quetiapine + olanzapine + risperidone	AstraZeneca	Pre-clinical	26
Asenapine 5-20 mg daily + Placebo 1-4 tablets daily	Merck	Approved	43
Ziprasidone HCL (oral)	Pfizer	Approved	35
Aripiprazole + Risperidone/Quetiapine	Bristol Myers Squibb	Pre-clinical	26
mifepristone + placebo	Corcept Therapeutics	Phase 3	29
Miricorlilant + Miricorlilant + Placebo	Corcept Therapeutics	Phase 2	32
Miricorilant + Fluvoxamine	Corcept Therapeutics	Phase 1	26
Miricorilant + Placebo	Corcept Therapeutics	Phase 2	32
Olanzapine + CORT118335 + Placebo	Corcept Therapeutics	Phase 1	26